Most patients with severe asthma switch or discontinue biologics
PHOENIX — More than half of patients with severe asthma changed biologics or discontinued treatment as they and their clinicians explored solutions, according to an abstract presented at the CHEST Annual Meeting.
However, trial-and-error approaches may lead to delays in disease control, higher costs and adverse effects, Isabella Novoa Caicedo, MD, postdoctoral research fellow, division of pulmonary, allergy and critical care medicine, Mayo Clinic, and colleagues wrote.
“There are now several biologics available for severe asthma, but we still do not have a clear roadmap for choosing among